Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss

Denmeade, 2010, Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer, Prostate, 70, 1600, 10.1002/pros.21196 Denmeade, 2021, TRANSFORMER: a randomized phase II study comparing bipolar androgen therapy versus enzalutamide in asymptomatic men with castration-resistant metastatic prostate cancer, J Clin Oncol, 39, 1371, 10.1200/JCO.20.02759 Markowski, 2021, A multicohort open-label phase II trial of bipolar androgen therapy in men with metastatic castration-resistant prostate cancer (RESTORE): a comparison of post-abiraterone versus post-enzalutamide cohorts, Eur Urol, 79, 692, 10.1016/j.eururo.2020.06.042 Beltran, 2019, The role of lineage plasticity in prostate cancer therapy resistance, Clin Cancer Res, 25, 6916, 10.1158/1078-0432.CCR-19-1423 Aparicio, 2016, Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers, Clin Cancer Res, 22, 1520, 10.1158/1078-0432.CCR-15-1259 Aparicio, 2013, Platinum-based chemotherapy for variant castrate-resistant prostate cancer, Clin Cancer Res, 19, 3621, 10.1158/1078-0432.CCR-12-3791 Corn, 2019, Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial, Lancet Oncol, 20, 1432, 10.1016/S1470-2045(19)30408-5 Markowski, 2022, Molecular and clinical characterization of patients with metastatic castration resistant prostate cancer achieving deep responses to bipolar androgen therapy, Clin Genitourin Cancer, 20, 97, 10.1016/j.clgc.2021.08.001 Nyquist, 2020, Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress, Cell Rep, 31, 107669, 10.1016/j.celrep.2020.107669